Exploding popularity of semaglutide among privately insured patients may worsen disparities
A new study led by Dima Qato, MPH, PhD, of the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Leonard D. Schaeffer Center for Health Policy and Economics suggests that publicly insured … Read More »